The LifeVest wearable cardioverter defibrillator is a therapeutic option in the continuum of care for your patients at risk for sudden cardiac death.

• LifeVest does not require any bystander intervention.
• LifeVest will attempt treatment for 100% of tachyarrhythmic SCA.
• LifeVest has a 98% first shock success rate.
• LifeVest has a 92% shock event survival with patients either staying at home or admitted conscious to the ER
• Over 19,000 patients have worn the LifeVest.
• LifeVest is listed as a therapeutic option in ACC/AHA/ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the prevention of Sudden Cardiac Death.
• LifeVest is a Class I recommendation in the 2006 International Society for Heart and Lung Transplantation Guidelines for the Care of Cardiac Transplant Candidates.